Paper Titles

Generating Porous Ceramic Scaffolds: Processing and Properties
p.155

Calcium Phosphate Ceramics as Bone Drug-Combined Devices
p.181

Bioactive Composites Based on Calcium Phosphates for Bone Regeneration
p.203

Dendritic Macromolecules: New Possibilities for Advanced Bioceramics
p.235

Biomineralization of Polymer Scaffolds
p.269

Functionalized Calcium Phosphate Nanoparticles for Biomedical Application
p.299

On Cancer Nanotechnology
p.307

Multifunctional Nano and Microparticles for Drug Delivery Systems
p.333

Drug Targeting and other Recent Applications of Magnetic Carriers in Therapeutics
p.357

HomeKey Engineering MaterialsKey Engineering Materials Vol. 441On Cancer Nanotechnology

On Cancer Nanotechnology

Article Preview

Abstract:

Although governments invest billions of dollars in cancer research, cancer remains one of the major causes of death worldwide (Liu et al., 2007). During the last decades, outstanding results have been attained in fundamental cancer biology but, unfortunately, they have not been translated in even distantly comparable progressions in the clinic. The main reason for this gap being the inability to administer therapeutic agents so that they can reach target cells without or with minimal side-effects (Ferrari, 2005). Today, scientists are faced with the recognition that very few molecules reach the desired locations and thus fail to selectively reach the target cells. Consequently, patients experience a very poor quality of life (Ferrari, 2004; Ferrari, 2005; Chan, 2006).

You might also be interested in these eBooks

Advanced Bioceramics in Nanomedicine and Tissue Engineering

Info:

Periodical:

Key Engineering Materials (Volume 441)

Pages:

307-332

DOI:

https://doi.org/10.4028/www.scientific.net/KEM.441.307

Citation:

Cite this paper

Online since:

June 2010

Authors:

Rita Bosetti, Lode Vereeck

Export:

RIS, BibTeX

Price:

Permissions:

Request Permissions

[1] ALEXIS F., PRIDGEN E., MOLMAR L.K., FAROKHZAD O.C., Factors affecting the clearance and biodistribution of polymeric nanoparticles, Molecular Pharmaceutics 5, 4 (2008), pp.505-515.

DOI: 10.1021/mp800051m

[2] ALEXIS F., RHEE J-W., RICHIE J.P., RADOVIC-MORENO A. F., LANGER R., FAROKHZAD O.C., ew frontiers in nanotechnology for cancer treatment, Urologic Oncology: Seminars and Original Investigations 26 (2008), pp.74-85.

DOI: 10.1016/j.urolonc.2007.03.017

[3] AKIN D., STURGIS J., RAGHEB K., SHERMAN D., BURKHOLDER K., ROBINSON J.P., BHUNIA A.K., MOHAMMED S., BASHIR R., Bacteria-mediated delivery of nanoparticles and cargo into cells, Nature Nanotechnology 2 (2007), pp.441-449.

DOI: 10.1038/nnano.2007.149

[4] CAPRI S., CATTANEO G., Cost-minimization analysis of pegylated liposomal doxorubicin versus topotecan for the treatment of ovarian cancer in Italy, Clinical Therapeutics 28, 6 (2003).

DOI: 10.1016/s0149-2918(03)80172-8

[5] CARUTHERS S.D., WICKLINE S.A., LANZA G.M., anotechnological applications in medicine, Current Opinion in Biotechnology 18 (2007), pp.26-30.

DOI: 10.1016/j.copbio.2007.01.006

[6] CHAN V.S.W., anomedicine: An unresolved regulatory issue, Regulatory Toxicology and Pharmacology 46 (2006), pp.218-224.

DOI: 10.1016/j.yrtph.2006.04.009

[7] CHERTOK B., MOFFAT B.A., DAVID A.E., YU F., BERGEMANN C., ROSS B.D., YANG V.C., Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors, Biomaterials 29, 4 (2007), pp.487-496.

DOI: 10.1016/j.biomaterials.2007.08.050

[8] CHO K., WANG X., NIE S., CHEN Z., SHIN D. M., Therapeutic nanoparticles for drug delivery in cancer, Clinical Cancer Res. 14, 5 (2008), pp.1310-1316.

DOI: 10.1158/1078-0432.ccr-07-1441

[9] DALLASTA L.M., PISAROV L.A., ESPLEN J.E., WERLEY J.V., MOSES A.V., NELSON J.A., ACHIM C.L., Blood-brain barrier tight junction disruption in human immuno deficiency virus-1 encephalitis, Am. J. pathol. 155, 6 (1999), p.1915-(1927).

DOI: 10.1016/s0002-9440(10)65511-3

[10] DECUZZI P., FERRARI M., The role of specific and non-specific interactions in receptormediated endocytosis of nanoparticles, Biomaterials 28 (2007), pp.2915-2922.

DOI: 10.1016/j.biomaterials.2007.02.013

[11] DUNCAN R., Polymer conjugates as anticancer nanomedicines, Nature Reviews 6 (2006), pp.688-701.

DOI: 10.1038/nrc1958

[12] FAN W., SUI M., HUANG Y., « Glucocorticoids selectively inhibit paclitaxel-induced apoptosis: Mechanisms and its clinical impact", Current Medicinal Chemistry 11 (2004), pp.403-411.

DOI: 10.2174/0929867043455990

[13] FAROKHZAD M.C., LANGER R., anomedicine: Developing smarter therapeutic and diagnostic modalities", Advanced Drug Delivery Reviews 58 (2006).

DOI: 10.1016/j.addr.2006.09.011

[15] FERRARI M., anovector therapeutics, Current Opinion in Chemical Biology 9 (2004), pp.343-346.

[16] FERRARI M., The mathematical engines of nanomedicine, Small Journal 4 (2008) p. (2025).

[17] GAO K., JIANG X., Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles, Pharmaceutical nanotechnology (2006).

DOI: 10.1016/j.ijpharm.2005.11.040

[18] GU F.X., KARNIK R., WANG A.Z., ALEXIS F., LEVY-NISSENBAUM E., HONG S., LANGER R.S., FAROKHZAD O.C., Targeted nanoparticles for cancer therapy, Nanotoday 2, 3 (2007), pp.14-21.

DOI: 10.1016/s1748-0132(07)70083-x

[19] HEATH J. R., DAVIS M. E., anotechnology and cancer, Annual Review of Medicine 59 (2008), pp.251-265.

[20] HELDIN C. -H., RUBIN K., PIETRAS K., OSTMAN A., High interstitial fluid pressure - An obstacle in cancer therapy, Nature Reviews 4 (2004), pp.806-813.

DOI: 10.1038/nrc1456

[21] HOLLIGER P., HUDSON P.J., Engineered antibody fragments and the rise of single domains, Nature Biotechnology 23 (2005), pp.1126-1136.

DOI: 10.1038/nbt1142

[22] HOLMBERG S.B., FORSSELL-ARONSSON E., GRETARSDOTTIR J., JACOBSSON L, RIPPE B., Vascular clearance by the reticulo-endothelial system - Measurements using two different-sized albumincolloids, Scandinavian Journal of Clinical and Laboratory Investigation 50, 8 (1990).

DOI: 10.3109/00365519009104954

[23] IMAI K., TAKAOKA A., Comparing antibody and small-molecule therapies for cancer, Nature Reviews Cancer 6 (2006), pp.714-727.

DOI: 10.1038/nrc1913

[24] JAIN K. K., Applications of nanobiotechnology in clinical diagnostics, Clinical Chemistry 53, 11 (2007), p.2002-(2009).

[25] JALLOULI Y., PAILLARD A., CHANG J., SEVIN E., BETBEDER D., Influence of surface charge and inner composition of porous nanoparticles to cross blood-brain barrier in vitro, International Journal of Pharmaceutics 344 (2007), pp.103-109.

DOI: 10.1016/j.ijpharm.2007.06.023

[26] JUILLERAT-JEANNERET L., The targeted delivery of cancer drugs across the bloodbrain barrier : Chemical modifications of drugs or drug-nanoparticles?, Drug Discovery Today 13, 23 (2008), pp.1099-1106.

DOI: 10.1016/j.drudis.2008.09.005

[27] KLOOVER J.S., DEN BAKKER M.A., GELDERBLOM H., VAN MEERBEECK J., Fatal outcome of a hypersensitivity reaction to paclitaxel: A critical review of premedication regimens, British Journal of cancer 90 (2004).

DOI: 10.1038/sj.bjc.6601303

[29] LEE KOO Y. -E., REDDY G.R., BHOJANI M., SCHNEIDER R., PHILBERT M.A., REHEMTULLA A., ROSS B.D., KOPELMAN R., Brain cancer diagnosis and therapy with nanoplatforms, Advanced Drug Delivery Reviews 58, 14 (2006), pp.1556-1577.

DOI: 10.1016/j.addr.2006.09.012

[30] LIU Y., MIYOSHI H., NAKAMURA M., « anomedicine for drug delivery and imaging : A promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles », International Journal of Cancer 120 (2007), pp.2527-2537.

DOI: 10.1002/ijc.22709

[31] LUNT S.J., KALLIOMAKI T.M.K., BROWN A., YANG V.X., MILOSEVIC M., HILL R.P., Interstitial Fluid Pressure, vascularity and metastasis in ectopic, orthotopic and spontaneous tumors, BMC Cancer 8, 2 (2008), 14p.

DOI: 10.1186/1471-2407-8-2

[32] MING-CHENG CHENG M., CUDA G., BUNIMOVICH Y.L., GASPARI M., HEATH J.R., HILL H.D., MIRKIN C.A., NIJDAM A.J., TERRACCIANO R., THUNDAT T., FERRARI M., anotechnologies for biomolecular detection and medical diagnostics, Current Opinion in Chemical Biology 10 (2006).

DOI: 10.1016/j.cbpa.2006.01.006

[33] MISRA A., GANESH S., SHAHIWALA A., Drug delivery to the central nervous system: A review, J. Pharm. Pharmaceut. Sci 6, 2 (2003), pp.252-273.

[34] OJEDA B., DE SANDE L.M., CASADO A., MERINO P., CASADO M.A., Costeffectiveness analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain, British Journal of Cancer 89, 6 (2003).

DOI: 10.1038/sj.bjc.6601228

[35] OWENS D.E., PEPPAS N.A., Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles, International Journal of Pharmaceutics 307, 1 (2006), pp.93-102.

DOI: 10.1016/j.ijpharm.2005.10.010

[36] OZBEN T., Mechanisms and strategies to overcome multiple drug resistance in cancer, FEBS Letters 580 (2006), pp.2903-2909.

DOI: 10.1016/j.febslet.2006.02.020

[37] PANCHAPAKESAN B., anotechnology: Tiny technology - tremendous therapeutic potential, Oncology Issues November/December (2005).

[38] PARK J.W., Lipsome-based drug delivery for breast cancer treatment, Breast Cancer Research 4 (2002), pp.95-99.

[39] PRASAD P.N., ROY I., BERGEY E.J., OHULCHANSKY T.Y., PUDAVAR H., Use of photodynamic therapy therapeutic agents entrapped in ceramic nanoparticles, Trends in Nanomaterials.

[40] PRATO M., KOSTARELOS K., BIANCO A., Functionalized carbon nanotubes in drug design and discovery", Accounts of Chemical Research 441 (2008).

DOI: 10.1021/ar700089b

[42] ROY I., OHULCHANSKYY T.Y., PUDAVAR H.E., BERGEY E.J., OSEROFF A.R., MORGAN J., DOUGHERTY T.J., PRASAD P.N., Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: A novel drug-carrier system for photodynamic therapy, Journal of the American Chemical Society 125, 26 (2003).

DOI: 10.1021/ja0343095

[43] SANVICENS N., MARCO M.P., Multifunctional nanoparticles - Properties and prospects for their use in human medicine, Trends in Biotechnology 26, 8 (2008), p.425433.

DOI: 10.1016/j.tibtech.2008.04.005

[44] SENGUPTA S., SASISEKHARAN R., Exploiting nanotechnology to target cancer, British Journal of Cancer 96 (2007), pp.1315-1319.

DOI: 10.1038/sj.bjc.6603707

[45] SINHA R., KIM G. J., NIE S., SHIN D. M., anotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery, Molecular Cancer Therapeutics 5, 8 (2006), p.1909-(1917).

DOI: 10.1158/1535-7163.mct-06-0141

[46] SMITH D.H., ADAMS J.R., JOHNSTON S.R.D., GORDON A., DRUMMOND M.F., BENNETT C.L., A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the U.S.A. and the U.K., Annals of Oncology 13 (2002).

DOI: 10.1093/annonc/mdf275

[47] SOUZA G.R., CHRISTIANSON D.R., STAQUICINI F.I., OZAWA M.G., SNYDER E.Y., SIDMAN R.L., MILLER J.H., ARAP W., PASQUALINI R., etworks of gold nanoparticles and bacteriophage as biological sensors and cell-targeting agents, PNAS 103, 5 (2006).

DOI: 10.1073/pnas.0509739103

[48] STEINFELD U., PAULI C., KALTZ N., BERGEMANN C., LEE H. -L., T lymphocytes as potential therapeutic drug carrier for cancer treatment, International Journal of Pharmaceutics 311 (2006), pp.229-236.

DOI: 10.1016/j.ijpharm.2005.12.040

[49] SURI S.S., FENNIRI H., SINGH B., « anotechnology-based drug delivery systems », Journal of Occupational Medicine and Toxicology (2), 2007, 6p.

[50] TAN K., CHEANG P., HO I.A., LAM P.Y., HUI K.M., anosized bioceramic particles could function as efficient gene delivery vehicles with target specificity for the spleen, Gene Therapy 14, 10 (2007), pp.828-835.

DOI: 10.1038/sj.gt.3302937

[51] TANAKA T., DECUZZI P., CRISTOFANILLI M., SAKAMOTO J.H., TASCIOTTI E., ROBERTSON F.M., FERRARI M., anotechnology for breast cancer therapy", Biomed Microdevices (2008).

DOI: 10.1007/s10544-008-9209-0

[53] TOMALIA D.A., REYNA L.A., SVENSON S., « Dendrimers as multi-purpse nanodevices for oncology drug delivery and diagnostic imaging », Biochemical Society Transactions 35 (2007), pp.61-67.

DOI: 10.1042/bst0350061

[54] TORCHILIN VP, Multifunctional nanocarriers, Advanced Drug Delivery Reviews 58 (2006), pp.1532-1555.

DOI: 10.1016/j.addr.2006.09.009

[55] TORCHILIN V., Multifunctional and stimuli-sensitive pharmaceutical carriers, European Journal of Pharmaceutics and Biopharmaceutics (2008).

[56] XiANG L., BIN W., HUALI J., WEI J., JIESHENG T., FENG G., YING L., Bacterial magnetic particles (BMPs)-PEI as a novel and efficiënt nonviral gene delivery system, The Journal of Gene Medicine 9 (2007), pp.679-690.

DOI: 10.1002/jgm.1068

[57] WANG X., YANG L., CHEN Z., SHIN D.M., Application of nanotechnology in cancer therapy and imaging, CA Cancer J Clin 58, 2 (2008), pp.97-110.

[58] WU H. -C., CHANG D. -K., HUANG C. -T., Targeted therapy for cancer, Journal of Cancer Molecules 2, 2 (2006), pp.57-66.

[59] YEZHELYEV M.V., GAO X., XING Y., AL-HAJJ A., NIE S., O'REGAN R.M., Emerging use of nanoparticles in diagnosis and treatment of breast cancer, Lancet Oncology 7 (2006), pp.657-667.

DOI: 10.1016/s1470-2045(06)70793-8

[60] YIH T.C., AL-FANDI M., Engineered nanoparticles as precise drug delivery systems, Journal of Cellular Biochemistry 97 (2006), pp.1184-1190.

DOI: 10.1002/jcb.20796

[61] ZHANG L., GU F.X., CHAN J.M., WANG A.Z., LANGER R.S., FAROKZHAD O.C., anoparticles in medicine: Therapeutic applications and developments, Clinical Pharmacology & Therapeutics 83, 5, pp.761-76.